OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $930.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2026-03-04
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2025 was $930.00K, a 21.09% increase from fiscal 2024.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2024 was $768.00K, a 156.86% increase from fiscal 2023.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2023 was $299.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|
| 2025-12-31 | $930.00K 10-K · filed 2026-03-04 |
| 2024-12-31 | $768.00K 10-K · filed 2025-03-05 |
| 2023-12-31 | $299.00K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |